The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer

NCT06959589 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic
KRAS G12C Mutation

Interventions

DRUG: IBI351, cetuximab β combined with FOLFIRI

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University